Employees: 01 (2023.0)Legal category: 5485Size: PMECreation date: 2006-04-15 (20 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: CHATELLERAULT (86100), Vienne
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIE NIOGRET-SANANIKONE : revenue, balance sheet and financial ratios
PHARMACIE NIOGRET-SANANIKONE is a French company
founded 20 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in CHATELLERAULT (86100),
this company of category PME
shows in 2025 a net income positive of 11 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE NIOGRET-SANANIKONE (SIREN 489929521)
Indicator
2025
2024
2023
2022
2021
2020
2018
2017
2016
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
10 717 €
6 221 €
33 361 €
57 280 €
68 563 €
73 666 €
100 720 €
29 557 €
940 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, PHARMACIE NIOGRET-SANANIKONE generates positive net income of 11 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2025: 940 € -> 11 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
10 717 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 30%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 69%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
29.71%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
69.07%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2020
2021
2022
2023
2024
2025
Debt ratio
146.379
93.374
69.803
24.716
23.621
29.118
34.027
30.243
29.71
Financial autonomy
31.787
35.917
46.851
63.758
66.605
66.123
66.235
68.092
69.07
Repayment capacity
None
None
None
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
29.712025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Good
In 2025, the debt ratio of PHARMACIE NIOGRET-SANANIKONE (29.71) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
69.07%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Good
In 2025, the financial autonomy of PHARMACIE NIOGRET-SANANIKONE (69.1%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 154.59. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2020
2021
2022
2023
2024
2025
Liquidity ratio
40.971
31.383
62.318
82.234
129.769
177.774
234.805
180.706
154.588
Interest coverage
None
None
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
154.592025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Average-28 pts over 3 years
In 2025, the liquidity ratio of PHARMACIE NIOGRET-SANANIKONE (154.59) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Positioning of PHARMACIE NIOGRET-SANANIKONE in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE NIOGRET-SANANIKONE is estimated at
170 240 €
(range 115 526€ - 267 131€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
115k€170k€267k€
170 240 €Range: 115 526€ - 267 131€
NAF 5 année 2025
Valuation method used
Net Income Multiple
10 717 €
×
15.9x
=170 241 €
Range: 115 526€ - 267 131€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE NIOGRET-SANANIKONE with other companies in the same sector:
Frequently asked questions about PHARMACIE NIOGRET-SANANIKONE
What is the revenue of PHARMACIE NIOGRET-SANANIKONE ?
The revenue of PHARMACIE NIOGRET-SANANIKONE is not publicly disclosed (confidential accounts filed with INPI).
Is PHARMACIE NIOGRET-SANANIKONE profitable?
Yes, PHARMACIE NIOGRET-SANANIKONE generated a net profit of 11 k€ in 2025.
Where is the headquarters of PHARMACIE NIOGRET-SANANIKONE ?
The headquarters of PHARMACIE NIOGRET-SANANIKONE is located in CHATELLERAULT (86100), in the department Vienne.
Where to find the tax return of PHARMACIE NIOGRET-SANANIKONE ?
The tax return of PHARMACIE NIOGRET-SANANIKONE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE NIOGRET-SANANIKONE operate?
PHARMACIE NIOGRET-SANANIKONE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart